Recent work has shown that CRISPR/dCas9 gene editing can be been used to activate PTEN transcription in breast cancer and melanoma cell lines that harbor wild-type PTEN alleles but have low PTEN expression in vitro [133]. The gene discussed is PTEN; the disease is melanoma.